CGP 79807Alternative Names: CGP-79807
Latest Information Update: 03 Apr 2003
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in Switzerland (unspecified route)
- 20 Sep 2000 New profile
- 20 Sep 2000 Preclinical development for Cancer in Switzerland (Unknown route)